DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Steroid-Antiviral Treatment in Rehabilitation of Facial Palsy

Information source: Assiut University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Facial Palsy

Intervention: Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Assiut University


The purpose of this study is to assess the efficacy of antiviral medicine (acyclovir) in complete recovery of facial Palsy. Fifty patients (Males and females) with acute Facial Palsy within the first 3 days of onset with age ranged from 15-60 years old. Each patient submitted to the following clinical evaluation using House and Brackmann6 facial function scoring system and Synnybrook grading system neurophysiological assessment of facial nerve and muscles before and after the end of treatment and then after the end of first and second month of treatment. EMG will be done for facial muscles of both sides beside measuring facial nerve excitability to determine the excitation threshold by recording the minimum electrical stimulus required to produce visible muscle contraction. A difference greater than 3. 5 mA between the affected and unaffected side is considered to be significant in terms of poor prognosis. Nerve conduction study of facial nerves of both sides using concentric needle electrode. Trigeminal Blink reflex for both side of the face. Facial functional recovery was defined as "good" or "complete" using the same criteria used in the 2001 practice guideline. Using the House and Brackmann6 facial function scoring system, we considered an outcome of grade I or II a good recovery.

Clinical Details

Official title: Antiviral Treatment in Facial Palsy. Randomized Control Trial

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Facial muscle function using clinical scale

Secondary outcome: Nerve conduction study of facial nerve.


Minimum age: 15 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- Acute onset facial palsy within the first three days of onset. Age ranged from 15-60

years old Exclusion Criteria:

- Patients with brittle diabetes mellitus, Morbid obesity, renal or liver impairment,

osteopenia, prior history of steroid intolerance.

Locations and Contacts

Additional Information

Starting date: April 2013
Last updated: December 26, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017